Last updated: 2026-09-07 20:44:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
PDS Biotechnology Corporation (PDSB) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0,22, with a market capitalization of $12,31M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,20 to $1,55. This page covers its latest market performance, valuation, price trends and company information.
$12,31M | |
$0,21 | |
$17,85 | |
$0,20 | |
$0,22 | |
1,05M | |
1,28M | |
-- | |
$1,55 | |
$0,20 | |
-- | |
-- |
PDS Biotechnology Corporation (PDSB) last closed at $0,22 as of 2026-09-04 23:53:00, unchanged from the previous close of $0,22.
During the latest regular trading session, PDSB traded between $0,20 and $17,85, with a volume of 1,05M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, PDS Biotechnology Corporation (PDSB) moved from $0,22 to $0,22, representing a gain of 0,96% ($0,00).
The stock traded between $0,20 and $0,24 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 960,18 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 1,8%
PDSB is currently trading at $0,22, placing it 1,8% of the way from its 52-week low of $0,20 to its 52-week high of $1,55. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 21 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of PDS Biotechnology Corporation (PDSB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.